Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CANOPY-A: Canakinumab as adjuvant therapy in completely resected NSCLC
jRCT2080223937Phase 3Completed
- Sponsor
- Novartis
- Start
- Jun 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing Canakinumab arm with Placebo arm (2 arms). Primary endpoint: Disease-free survival. Started Jun 2018; status: completed.
02
Drugs
canakinumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2080223937.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223937.